新型抗癌药物ONC201，抗癌药物与MD安德森的合作重点

MD Anderson新闻发布于2015年1月5日

MD安德森新闻发布01/05/2015

---

Oncoceutics Inc.和Texas MD Anderson Constens中心今天宣布启动战略联盟和研究合作协议，为新型抗癌药物的临床发展临床发展。188bet体育网址

早些时候，ONC201的临床前研究表明，该药物有进一步研究的价值，它似乎可以杀死癌细胞而不伤害健康细胞。oncoeutics和MD Anderson的协议将导致特定血液学肿瘤的临床试验。

这种非传统联盟与MD Anderson和Oncoceutics之间的旨在使癌症患者的转化性药物临床开发。预计协作将迅速识别在肿瘤学中使用ONC201的最佳临床环境。战略协议还规定了持续存在风险和潜在商业化。

“We and others have conducted extensive preclinical studies on ONC201 before considering such an agreement and are hopeful that drug may turn into a valuable remedy against several malignancies,” said Michael Andreeff, M.D., Ph.D., chief of molecular hematology and therapy , professor of medicine, and the Paul and Mary Haas Chair in Genetics. “ONC201’s broad activity in a range of tumors, combined with benign toxicity, allows us to offer this clinical trial drug to patients who have exhausted their therapeutic options and can no longer tolerate aggressive treatments.”

“在MD安德森，我们致力于创新，并将新发现转化为临床实践，”MD安德森的系主任和白血病研究主席Kelcie Margaret Kana医学博士说。188bet体育网址“我们的最高目标是找到创新组合中的精华，并加速将其引入临床应用。我们认为ONC201值得探索，以验证其作为抗癌药物的潜在作用。最终，我们努力为癌症患者提供更多更好的选择。”

“It is a privilege to work with the MD Anderson team on the development of ONC201 and the ambitious nature of the program speaks more than words can tell of the excitement behind the drug,” said Wolfgang Oster, M.D., Ph.D., chief executive officer of Oncoceutics.